The chi-squared test will be applied to evaluate the heterogeneity. If I2>50%, trials would be considered with significant heterogeneity, and subgroup analysis will be necessarily performed to assess the potential heterogeneity sources, these sources possibly include the onset time, duration, type of HF, etc.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.